News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioForm Inc. Announces Closing of IPO and Exercise of Underwriters' Over-Allotment Option


11/15/2007 10:47:20 AM

SAN MATEO, Calif., Nov. 14 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. announced that on November 13, 2007, it closed its previously announced initial public offering of 10,000,000 shares and that the underwriters of the offering exercised their over-allotment option in full and purchased 1,500,000 additional shares of common stock at the public offering price of $8.00 per share. Including the over-allotment, the company sold 11,500,000 shares in the offering, resulting in net proceeds of approximately $83.4 million after deducting the underwriting discounts and commission and the estimated offering expenses.

J.P. Morgan Securities Inc. and Piper Jaffray & Co. are serving as joint book-running managers for the offering, with CIBC World Markets Corp. and Jefferies & Company, Inc. serving as co-managers.

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A copy of the final prospectus for the offering may be obtained from the prospectus department of either J.P. Morgan Securities Inc., 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, or by calling (718) 242-8002; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by calling (877) 371-5212.

About BioForm Medical, Inc.:

BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California. BioForm's products include Radiesse(R), a long-lasting filler for use in facial aesthetics and vocal fold insufficiency, and Coaptite(R) for treating female stress urinary incontinence which is marketed through a partnership with Boston Scientific Corporation.

CONTACT: Adam Gridley, Vice President, Corporate Development of BioForm
Medical, Inc., +1-650-286-4025

Web site: http://www.bioformmedical.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES